Literature DB >> 15718241

Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism.

Sarah L Cole1, Aneta Grudzien, Ingrid O Manhart, Brent L Kelly, Holly Oakley, Robert Vassar.   

Abstract

The use of statins, 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors that block the synthesis of mevalonate (and downstream products such as cholesterol and nonsterol isoprenoids), as a therapy for Alzheimer disease is currently the subject of intense debate. It has been reported that statins reduce the risk of developing the disorder, and a link between cholesterol and Alzheimer disease pathophysiology has been proposed. Moreover, experimental studies focusing on the cholesterol-dependent effects of statins have demonstrated a close association between cellular cholesterol levels and amyloid production. However, evidence suggests that statins are pleiotropic, and the potential cholesterol-independent effects of statins on amyloid precursor protein (APP) metabolism and amyloid beta-peptide (A beta) genesis are unknown. In this study, we developed a novel in vitro system that enabled the discrete analysis of cholesterol-dependent and -independent (i.e. isoprenoid-dependent) statin effects on APP cleavage and A beta formation. Given the recent interest in the role that intracellular A beta may play in Alzheimer disease, we analyzed statin effects on both secreted and cell-associated A beta. As reported previously, low cellular cholesterol levels favored the alpha-secretase pathway and decreased A beta secretion presumably within the endocytic pathway. In contrast, low isoprenoid levels resulted in the accumulation of APP, amyloidogenic fragments, and A beta likely within biosynthetic compartments. Importantly, low cholesterol and low isoprenoid levels appeared to have completely independent effects on APP metabolism and A beta formation. Although the implications of these effects for Alzheimer disease pathophysiology have yet to be investigated, to our knowledge, these results provide the first evidence that isoprenylation is involved in determining levels of intracellular A beta.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15718241     DOI: 10.1074/jbc.M413895200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

Review 1.  Neuronutrition and Alzheimer's disease.

Authors:  Balenahalli N Ramesh; T S Sathyanarayana Rao; Annamalai Prakasam; Kumar Sambamurti; K S Jagannatha Rao
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 2.  Beta-secretase: structure, function, and evolution.

Authors:  Chitra Venugopal; Christina M Demos; K S Jagannatha Rao; Miguel A Pappolla; Kumar Sambamurti
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-06       Impact factor: 4.388

Review 3.  Protein prenylation and synaptic plasticity: implications for Alzheimer's disease.

Authors:  David A Hottman; Ling Li
Journal:  Mol Neurobiol       Date:  2014-01-05       Impact factor: 5.590

4.  Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers.

Authors:  Alberto Serrano-Pozo; Gloria L Vega; Dieter Lütjohann; Joseph J Locascio; Marsha K Tennis; Amy Deng; Alireza Atri; Bradley T Hyman; Michael C Irizarry; John H Growdon
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Jul-Sep       Impact factor: 2.703

5.  Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance.

Authors:  Mitsuru Shinohara; Naoyuki Sato; Hitomi Kurinami; Daisuke Takeuchi; Shuko Takeda; Munehisa Shimamura; Toshihide Yamashita; Yasuo Uchiyama; Hiromi Rakugi; Ryuichi Morishita
Journal:  J Biol Chem       Date:  2010-05-14       Impact factor: 5.157

6.  Statins inhibit the dimerization of beta-secretase via both isoprenoid- and cholesterol-mediated mechanisms.

Authors:  Richard B Parsons; Gemma C Price; Joanna K Farrant; Daryl Subramaniam; Jubril Adeagbo-Sheikh; Brian M Austen
Journal:  Biochem J       Date:  2006-10-15       Impact factor: 3.857

Review 7.  Isoprenoids, small GTPases and Alzheimer's disease.

Authors:  Gero P Hooff; W Gibson Wood; Walter E Müller; Gunter P Eckert
Journal:  Biochim Biophys Acta       Date:  2010-04-08

Review 8.  Linking lipids to Alzheimer's disease: cholesterol and beyond.

Authors:  Gilbert Di Paolo; Tae-Wan Kim
Journal:  Nat Rev Neurosci       Date:  2011-03-30       Impact factor: 34.870

Review 9.  β-Secretase: its biology as a therapeutic target in diseases.

Authors:  Haibo Wang; Rena Li; Yong Shen
Journal:  Trends Pharmacol Sci       Date:  2013-02-27       Impact factor: 14.819

10.  Membrane cholesterol as regulator of human rhomboid protease RHBDL4.

Authors:  Sandra Paschkowsky; Sherilyn Junelle Recinto; Jason C Young; Ana-Nicoleta Bondar; Lisa Marie Munter
Journal:  J Biol Chem       Date:  2018-08-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.